Header

Thyroid Cancer Clinical Trials

Category:Adult
Status:Active

Displaying 1 trial

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

First-in-human, Phase 1b safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an intravenous infusion once every three weeks. Patients with tumor types likely to express NaPi2...

Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Thyroid Cancer, GYN: Endometrial/Uterine Cancer, Solid Tumor/Phase I, Lung Cancer

Phase:

Protocol Number: 17-621

'